This study examines the absolute numbers and relative proportions of CD4 þ , CD8 þ , CD14 þ and CD34 þ cells contained in allografts and their impact on early engraftment and later clinical outcomes in 141 patients with hematological malignancies who underwent unmanipulated HLA-mismatched/haploidentical hematopoietic SCT without in vitro T-cell depletion. These patients received G-CSF-primed BM grafts (G-BM) and peripheral blood grafts (G-PB) following a modified regimen of BU/CY 2 plus antithymocyte globulin. Multivariate analysis showed that high CD34 þ cell numbers were associated with accelerated plt engraftment (P ¼ 0.001). Meanwhile, patients with a higher CD4/CD8 ratio in G-BM (X1.16) had a survival disadvantage (Po0.01) and a trend towards relapse (P ¼ 0.086) after controlling for disease status. A higher CD4/CD8 was also associated with a significantly increased risk of acute GVHD grades II-IV (P ¼ 0.013), even after adjusting for an ABO major mismatch. No aspect of graft composition affected neutrophil engraftment or chronic GVHD. In conclusion, the differences in CD34 þ cell dose and the CD4/CD8 ratio in grafts seem to affect engraftment and clinical outcomes; in particular, a lower CD4/CD8 ratio in primed BM graft is associated with a survival benefit.
Introduction
In allogeneic hematopoietic SCT (allo-HSCT), the dose of certain cell types is known to affect engraftment kinetics and clinical outcome. For example, higher doses of CD34 þ stem cells are associated with rapid neutrophil and/or plt engraftment after G-CSF-primed PBSC transplantation (G-PBSCT) or BMT. [1] [2] [3] It has been suggested that beyond a critical threshold dose of T-cell dose, perhaps 1 Â 10 5 to 1 Â 10 6 per kg of patient body weight, increasing the dose does not necessarily result in a higher incidence of GVHDs. 4 However, recent studies have reported that infusion of G-PBSC with a low dose of CD8 þ T cells may adversely affect T-cell engraftment, fungal infection and survival outcome. 5 Another study showed that the large number of CD14 monocytes in G-PBMCs may limit T-cell responsiveness by suppressing costimulatory signals, thereby influencing the incidence or severity of acute GVHD (aGVHD). 6 However, the absolute numbers of certain cells in the graft is not the only predictor of outcome. Zaucha et al. showed that the ratio of CD3:CD14 cells in G-CSF-mobilized PBMCs products was significantly associated with clinical outcome in HLA-identical sibling transplantation. 7 This indicates an influential role of relative proportions in grafts for transplantation.
Traditionally, steady-state BM and G-CSF-primed PBSCs (G-PB) have been the source of stem cells. In recent years, G-CSF-primed BM (G-BM) has become an alternative source for HSCT. G-BM transplantation has a similar engraftment rate as allo-PBSCT and BMT, with a similar or even lower incidence of acute GVHD and chronic GVHD (cGVHD). 8, 9 Encouragingly, a combination of allogeneic G-BM cells with G-PB cells appears to be a promising progenitor cell source for HLA-mismatched/haploidentical HSCT. 10, 11 These mixture grafts (G-BM and G-PB) offer different results than the usual myeloablative transplantation strategies using 'megadose' stem cells vigorously depleted of T cells for patients without an HLA-matched donor. 12, 13 The mixture grafts (G-BM and G-PB), without in vitro T-cell depletion, lead to rapid and stable engraftment and strong GVL, without significantly increasing the incidence of aGVHD and cGVHD. 10, 11 In vitro tests have shown that mixture grafts are specifically associated with T-cell hyporesponsiveness and polarization. [14] [15] [16] However, the exact impact of graft composition on clinical outcome after this transplantation remains unclear. Therefore, we prospectively analyzed data from patients with hematological malignancies who underwent HLA-mismatched/haploidentical HSCT without in vitro T-cell depletion and studied the associations between infused cell doses and clinical outcomes. Between 31 October 2002 and 25 January 2007, 141 consecutive patients treated with HLA-mismatched/haploidentical HSCT without in vitro T-cell depletion were included in the study. We enrolled patients with hematological malignancies suitable for allo-HSCT, who had no HLA-identical-related or unrelated donors. The characteristics of the patients and transplantations are summarized in Table 1 . All patients were treated for an hematologic malignancy, which was acute leukemia in 76 patients (54%). Donors were parents and siblings in 94% of the cases and children in the remainder.
Materials and methods

Patients and eligibility
All patients were uniformly treated with a myeloablative regimen (the GIAC protocol 10, 11 ) before infusion of unmanipulated G-BM and G-PB. The infusion was followed by GVHD prophylaxis as described previously. 10, 11 Patients and donors were allele-level molecular typed at HLA-A, -B, -C and -DRB1. Donors were ranked on the basis of the best HLA match, age (younger preferred), relationship (mother preferred), gender (same preferred) and health status (better preferred). Donors were given rhG-CSF 5 g/kg per day for 5-6 days. On the 4th day, BM cells were harvested with a target mononuclear cell count (MNC) of 3 Â 10 8 to 4 Â 10 8 per kg recipient weight. On the 5th and 6th days, PBPCs were collected with the same target cell count. The fresh and unmanipulated BM and PBSCs were infused into the recipient on the day of collection. All patients provided informed consent for treatment under the protocol reviewed and approved by Peking University Institute of Hematology.
For the present analysis, patients were grouped according to the underlying malignancy and remission status at transplantation into high risk (acute leukemia beyond second remission, not in remission or had high-risk cytogenetics remission; myelodysplastic syndrome (MDS)-refractory anemia with excess of blasts in transformation (RAEB-t) or MDS-AML; CML beyond first chronic phase, hybrid acute leukemia) and standard risk (other than described above). A total of 88 (62%) patients were categorized as having 'high risk' at the time of HSCT.
Flow cytometry evaluation of graft composition
Samples from grafts (G-BM and G-PB) were stained with MoAb for flow cytometry analysis of the following surface Ags: CD45, CD3, CD4, CD8, CD14, CD34. CD34 þ cell enumeration was performed at Peking University People's Hospital, essentially as described by Liu et al. 17 The absolute numbers of CD3 þ , CD4 þ and CD8 þ T cells were, respectively, calculated as percentage of CD3 þ , CD3 þ CD4 þ , CD3 þ CD8 þ or CD14 þ cells labeled by a three-or four-color Ab cocktail within the side scatter low and CD45 þ lymphocyte gate multiplied by the total MNC, and divided by actual patient weight to determine cell dose per kg. Acquisition and analyses were performed with CellQuest software (Becton-Dickinson, San Jose, CA, USA).
Study definitions
Engraftment, GVHD, relapse, treatment-related mortality (TRM), and survival were the study endpoints. Neutrophil engraftment was defined as the first of 3 consecutive days with neutrophils more than 0.5 Â 10 9 per l during the first 60 days after transplantation. Plt engraftment was defined as the first of 7 days of unsupported plts more than 20 Â 10 9 per l during the first 180 days after transplantation. Patients were evaluated for aGVHD after successful engraftment, and for cGVHD if they survived for at least 100 days after HSCT. The GVHD was diagnosed and graded based on the Seattle criteria. 18, 19 Relapse rate was defined as the probability of disease recurrence. TRM was defined as the probability of dying without recurrence of disease. Overall survival (OS) was defined as days from transplantation to death from any cause. Disease-free survival (DFS) was defined as the probability of being alive and free of disease at any point in time with death or disease relapse as events.
Statistical analysis
The reference date of 1 September 2007, was used as the end of follow-up. Spearman's rank correlation coefficients were used to estimate the relationships among the graft composition variables. The distributions of graft composition were compared for homogeneity using the Wilcoxon's rank sum test. If the correlation coefficients are higher than 0.8, colinearity may exist between the variables and some factors should be controlled accordingly in the statistical model. 20 CD4 þ , CD8 þ , CD14 þ , CD34 þ cell dose were introduced after dichotomization at a cutoff of 50th percentile; the CD4/CD8 ratio was also introduced to display the distribution of T-cell subsets after the same dichotomization, which are shown in Table 2 . In addition to neutrophil and plt engraftment, the following clinical outcomes: aGVHD, cGVHD, relapse, TRM, DFS and OS in relationship to cellular graft composition were considered. The predictive effect of each of the following variables was assessed: recipient and donor ages, recipient and donor genders, gender match, HLA mismatch, ABO compatibility, ABO major mismatch, female donor to a male recipient, donor-recipient relationship, diagnosis and risk of disease (high or standard). A cumulative incidence model was used to estimate the time to engraftment, aGVHD, cGVHD, OS and DFS, identifying death as a competing risk. Comparison of cumulative incidence curves used the Gray test. 21 Cox proportional hazards univariate and multivariate regression models were used to identify predictors of study endpoints. The final multivariate models were determined using a backward selection procedure, and the P-value of 0.05 was the threshold for the inclusion and exclusion of variables. All analyses were performed using the SPSS 13.0 and NCSS software packages (version 2001; NCSS, Kaysville, UT, USA). Table 2 shows the subtypes of cells from G-BM and G-PB infused at transplantation for 141 HSC recipients; the median and range for CD3 þ , CD4 þ , CD8 þ , CD14 þ , CD34 þ , CD4/CD8 ratio are given, each demonstrating broad ranges. Although there was no difference in the total MNC between G-PB and G-BM, the dose of CD34 þ cells in G-PB was 2-3 times that in G-BM and the doses of CD3 þ , CD4 þ , CD8 þ , CD14 þ cells in G-PB were about 7-10 times those in G-BM. Table 3 shows the correlation coefficients of various cell components of the grafts with one another. Almost all cell subtypes showed statistically significant positive linear relationships with one another. These linear relationships were especially strong between certain cellular subsets (for example CD3 þ cells and CD4 þ cells, CD3 þ cells and CD8 þ cells; correlation coefficients40.8), which indicated that in the subsequent analyses of clinical outcomes these cellular subsets could not be regarded as completely independent factors. In fact, cell subtypes like CD4 þ , CD8 þ , CD14 þ , CD34 þ , and their relative proportions were selected factors in the statistical model.
Results
Cellular composition of grafts and correlation between cells types
Engraftment
All patients achieved neutrophil engraftment, but 14 patients subsequently died before achieving a plt count of X20 Â 10 9 per l. Cumulative estimated incidence of plt recovery by day 180 was 98.5%. Cumulative estimated incidence of plt recovery was 100 versus 96.8% in patients receiving more or less than the 50th percentile dose of Table 2 Graft product composition characteristics CD34 þ cells, respectively ( Figure 1) . Results of multivariate analysis showed that a dose of CD34 þ cells above the 50th percentile was associated with faster plt engraftment (hazard ratio (HR) ¼ 1.913; 95% confidence interval (CI) ¼ 1.314-2.786, P ¼ 0.001), but the dose did not affect the engraftment of neutrophils (Table 4) .
GVHD
A total of 62 (43%) patients developed grades II-IV aGVHD with a cumulative rate of 52.8% at day 100. aGVHD of grades III and IV occurred in 15 (10.6%) patients with a cumulative rate of 13.3% at day 100. ABO major mismatch and a CD4/CD8 ratio X1.16 in primed BM were found to correlate significantly with an increased incidence of grades II-IV aGVHD. By applying a multivariate model, a high CD4/CD8 ratio in the G-BM was the cellular factor most strongly associated with the severity and probability of developing aGVHD (HR ¼ 2.092; 95% CI ¼ 1.172-3.735, P ¼ 0.013). Figure 2a shows the difference in incidence of grades II-IV aGVHD according to the CD4/CD8 ratio in G-BM. cGHVD developed in 78 of the 125 patients who survived beyond 100 days after transplantation, 24 of whom had extensive disease. In the multivariate analyses, none of the cell-type variables were significantly associated with cGVHD (Table 4) .
Survival
With a median following-up time of 592 days (range, 137-1640 days) for surviving patients, 111 patients were alive, and 30 patients had died up to the 1 September 2007. The causes of death included recurrent leukemia in 7 patients, and TRM in 23 patients. Of 141, 11 patients had relapses or disease progression in the absence of rejection; 7 of these 11 patients subsequently died, and 4 were still alive with disease progression. At 2 years, DFS was 71% (95% CI: 66-76) and OS was 75% (95% CI: 70-80). In the Cox multivariate analysis, a high risk of disease and a CD4/CD8 ratio X1.16 in G-BM were associated with a worse TRM, DFS and OS (Table 4 ; Figure 2c ). Kaplan-Meier estimates of DFS and OS according to CD4/CD8 ratio in G-BM are shown in Figure 3a and b (P ¼ 0.008; P ¼ 0.006, respectively). There was also a trend toward an increased risk of relapse in patients with a higher ratio in G-BM (P ¼ 0.086), even after adjusting for the disease category (Figure 2b ). Among patients receiving grafts with higher CD4/CD8 ratios in G-BM, the most common cause of death was infection or multiorgan failure (52.4%, data not shown). Univariate analyses of clinical characteristics for survival showed there was no effect of extensive cGVHD or aGVHD (grades II-IV) on OS or DFS; as expected, a diagnosis of advanced disease status correlated with worse DFS and OS (P ¼ 0.001; P ¼ 0.002, respectively, data not shown).
Discussion
In the present study, we found that the CD34 þ cell dose was positively associated with faster plt engraftment, but unrelated to neutrophil engraftment. The importance of the CD34 þ cell dose has been widely demonstrated in G-PBSCT and BMT. [1] [2] [3] Results from some studies furthermore suggested that a relatively low CD34 þ cell dose, between 2 Â 10 6 and 4 Â 10 6 per kg of patient body weight, is the minimum required for rapid or durable engraftment. 22 In contrast, Slowman et al. 23 found that grafts with more CD34 cells were not associated with faster neutrophil engraftment, and other clinical analyses support 
that conclusion. [24] [25] [26] [27] In our study, almost all patients achieved satisfactory hematopoietic engraftment, although the mean number of infused CD34 þ cells was relatively low (2.14(0.46-9.69) Â 10 6 per kg). This implies that the high number of T cells infused may help to the engraftment of plt, as suggested by Zaucha et al.; 28 however, the interaction between T-cell subsets and CD34 cells in engraftment is difficult to verify. Another possibility is that most grafts in our patients contained more than the minimum number of progenitor cells (CD34 þ ) needed for optimal neutrophil engraftment.
In our transplant settings, HLA disparity did not correlate with aGVHD or cGVHD, nor with those factors analyzed by Huang et al., 10 that is, sex mismatch, age of donor or patients, diagnosis and risk of disease. Instead, aGVHD was influenced by ABO major mismatch and CD4/CD8 ratio in primed BM. Conflicting data still exist as to the influence of ABO mismatch on GVHD and survival. Bacigalupo et al. 29 and Stussi et al. 30 suggested that ABO incompatibility represents a risk factor for aGVHD after allogeneic SCT. A possible reason may be that broadly distributed ABO Ags may damage the host endothelium, potentially triggering GVHD in incompatible SCT. The CD4/CD8 ratio, as a routine measure of immune function and response, is genetically controlled in healthy people. Recent studies showed evidence that most T-cell alloreactivity resided within the CD4 þ T-cell subset, 31 and central memory CD4 þ T cells in grafts increased the incidence of aGVHD. 32 The importance of this subset in inducing aGVHD is presumably linked to its involvement in helping CD8 þ T cells, stimulating antigen-presenting cells, and sustaining immunologic memory. A recent finding by Rezvani et al. 33 showed that a high content of FOXP3-positive regulatory T cells (Treg) in the donor is associated with a low risk of GVHD after HLA-matched allogeneic SCT. Although no impact on CD4 þ CD25 þ regulatory T cells in BM graft was found after in vivo rhG-CSF application, 15 the correlation of this T-cell subset with GVHD is being investigated in our institution. Whatever the explanation, it should be emphasized that an association was unequivocally found between CD4/CD8 ratio and aGVHD in the present study.
In contrast, no link between cGVHD and CD4/CD8 ratio in the allograft was found. cGVHD is thought to be closely associated with aGVHD, but recent studies indicate that besides the time of onset, cGVHD and aGVHD differ both clinically and pathobiologically. 34, 35 In addition, aGVHD does not necessarily develop into cGVHD, nor does cGVHD necessarily follow aGVHD. Moreover, cGVHD involves pathogenic autoreactivity in addition to alloreactivity. 36, 37 Perhaps, autoreactive post-thymic T cells generated from infused CD34 þ cells in allografts increase the probability of cGVHD and confound the contribution of a higher CD4/CD8 ratio in primed bone marrrow. A further study may be warranted to clarify the involvement of CD4/CD8 ratio in aGVHD and cGVHD.
Clinical categorization has been identified as a significant predictor of survival in previous studies. 10 However, the most encouraging finding in this report was a significant association between lower CD4/CD8 ratio in G-BM and improved survival endpoints (that is, OS and DFS). Although the biologic basis for this is not clear, it may be because of a lower TRM or a lower incidence of relapse.
The excessive mortality appears more dependent on TRM than on aGVHD alone in the patients with higher CD4/ CD8 ratios in G-BM from our analysis.
G-BM for allogeneic transplantation has been evaluated in a series of patients with accelerated neutrophil and plt engraftment. Compared with unstimulated BM, G-BM contained similar numbers of nucleated cells, CD34 þ cells, and CD3 þ cells; in contrast, the numbers of CD34 þ cells and CD3 þ (CD4 þ and CD8 þ ) cells in G-PB were, repectively, 2-to 3-fold and 7-to 10-fold greater than the numbers in G-BM in our study. As regards the relative proportions of cell subsets in grafts, the CD4/CD8 ratio was markedly decreased in primed marrow grafts from HSC donor after standard mobilization, but unaffected in the primed PB grafts. 9, 14 Our preliminary data indicated that G-CSF led to the induction of T-cell hyporesponsiveness and the alteration of immunological cells in BM or PBSC grafts. 14, 15 These immunological characteristics have been demonstrated in clinical settings, as the use of G-BM results in less GVHD and comparable engraftment as G-PBSC. 8 It is conceivable that differences in the proportion of cell subsets (for example, CD4/CD8 ratio) could compensate for differences in the absolute numbers of them in grafts. More importantly, patients in our study received G-BM and G-PB on successive days, so the biological features of each, or the total graft, may differ. Although the univariate analyses suggested some cell types in G-PB or the total graft associated with transplant outcome, the multivariate analyses did not support these associations, except regarding CD34 þ cells in the total graft for plt engraftment (Table 4; Supplementary  Table S1 -2).
Haploidentical HSCT has become a good alternative for patients with hematological malignancies who do not have a matched related or unrelated donor. Tabilio et al. 13 and Dey and Spitzer 12 suggested a megadose of hematopoietic progenitor cells, very few T lymphocytes, or selective depletion of alloreactive T cells in preparing a graft for haploidentical transplants. However, in our study, with a relatively small dose of stem cells and more T cells, the patients underwent HLA-mismatched/haploidentical transplant with potentially acceptable outcomes. More recently, data show that CD3 þ cell dose significantly correlates with overall outcome in this transplant protocol. 38 Highlighted by results from our analysis is the further finding that the CD4/CD8 ratio in primed BM had a significant impact on clinical outcomes: lower CD4/CD8 ratio may predict lower incidence of aGVHD and relapse, and would bring beneficial effects to TRM, DFS and OS. Hence, as Zaucha et al. 7 and Yakoub-Agha et al. 32 suggested that it may be not only the absolute numbers of cell subtypes, but also the ratio among them that affects functional status of grafts and determines clinical outcomes. This may provide another important variable that can be manipulated in graft engineering in the future. It is of note that in our study only CD4 þ , CD8 þ , CD14 þ , CD34 þ cells were evaluated; other accessory cells, such as natural killer cells, DC and antigen-specific CTLs, may prove to be predictive of outcome. We hope that ongoing research will help to optimize outcome after HLA-mismatched/haploidentical HSCT.
